Progesterone receptor

Target id: 627

Nomenclature: Progesterone receptor

Systematic Nomenclature: NR3C3

Family: 3C. 3-Ketosteroid receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

Gene and Protein Information
Species AA Chromosomal Location Gene Symbol Gene Name Reference
Human 933 11q22-q23 PGR progesterone receptor 32
Mouse 926 9A1 Pgr progesterone receptor 34
Rat 923 8q11 Pgr progesterone receptor 20
Previous and Unofficial Names
PGR
nuclear receptor subfamily 3 group C member 3
progestin receptor form A
progestin receptor form B
PR
PR-A
PR-B
Database Links
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
GeneCards
GenitoUrinary Development Molecular Anatomy Project
HomoloGene
Human Protein Reference Database
InterPro
KEGG Gene
NURSA Receptor
OMIM
PharmGKB Gene
PhosphoSitePlus
RefSeq Nucleotide
RefSeq Protein
TreeFam
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Progesterone receptor-ligand-binding domain bound to an agonist
PDB Id:  3D90
Ligand:  levonorgestrel
Resolution:  2.26Å
Species:  Human
References:  37
Natural/Endogenous Ligands
progesterone
Rank order of potency (Human)
progesterone
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
medroxyprogesterone Hs Agonist 9.47 pKi 57
pKi 9.47 (Ki 3.4x10-10 M) Affinity at human PR-A [57]
mifepristone Hs Mixed 8.96 pKi 58
pKi 8.96 (Ki 1.1x10-9 M) [58]
progesterone Hs Agonist 8.46 pKi 57
pKi 8.46 (Ki 3.5x10-9 M) Affinity at human PR-A [57]
dydrogesterone Hs Agonist 6.9 pKi 40,43
pKi 6.9 (Ki 1.26x10-7 M) Binding to PRs on MCF-7 cells [40,43]
progesterone Hs Agonist 8.82 pEC50 12
pEC50 8.82 (EC50 1.5x10-9 M) [12]
norethisterone Hs Agonist 8.66 pEC50 11
pEC50 8.66 (EC50 2.2x10-9 M) [11]
ulipristal acetate Hs Partial agonist <7.0 pEC50 38
pEC50 <7.0 (EC50 >1x10-7 M) [38]
tanaproget Hs Agonist 9.3 pIC50 14
pIC50 9.3 (IC50 5x10-10 M) [14]
Description: Displacement of [3H]R5020 from human progesterone receptor expressed in T47D cells.
levonorgestrel Hs Agonist - - 5,43
[5,43]
ORG2058 Hs Agonist - -
[3H]ORG2058 Hs Agonist - -
promegestone Hs Agonist - - 43
[43]
Agonist Comments
All bind in the low to high nanomolar range but reported values range widely depending on assay conditions.

Although there is no specific data available for levonorgestrel, its relative affinity for progesterone receptors in MCF-7 cells is approximately 2.5 times higher than the affinity of progesterone [5]. In addition levonorgestrel is 140 times more potent than progesterone in inducing sexual behavior in rats [24]. Org 2058 has affinity similar to levonorgestrel [5].
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
mifepristone Hs Mixed 8.96 pKi 58
pKi 8.96 (Ki 1.1x10-9 M) [58]
onapristone Hs Antagonist 7.74 pKi 18
pKi 7.74 (Ki 1.8x10-8 M) [18]
ulipristal acetate Hs Antagonist 9.7 pIC50 38
pIC50 9.7 (IC50 2x10-10 M) [38]
ZK112993 Hs Antagonist - -
asoprisnil Hs Antagonist - - 43
[43]
Antagonist Comments
Binding affinity depends upon the assay and laboratory measuring it, thus the compounds are ranked in order of binding affinity using relative binding affinity (RBA). All bind in the low to high nanomolar range. Mifepristone and Asoprisnil possess tissue specific partial agonist activity [43].
DNA Binding
Structure:  Homodimer
HRE core sequence:  GGTACANNNTGTTCT
Response element:  GRE, Palindrome
DNA Binding Comments
Highly purified PR binds its response element with low affinity. Addition of nuclear extract or purified HMGB restores DNA binding affinity. In addition to direct response elements, PR can influence gene expression through a "tethering mechanism" independent of PR DNA binding by interacting with other DNA bound transcription factors.
Co-binding Partners
Name Interaction Effect Reference
Hsp90 Physical Cellular localization 13,50
HMGB Physical, Functional DNA binding 6,35
Src family kinases Physical activation of rapid signaling cascades, independent of PR DNA binding. 7
Main Co-regulators
Name Activity Specific Ligand dependent AF-2 dependent Comments References
NCOA1 Co-activator No Yes Yes Steroid-receptor coactivator-1 (SRC-1) appears to be a general coactivator for steroid receptors, preferred member of the p160 family for PR 26,28,44,46,49
NCOA3 Co-activator Yes Yes No 1,8
CREBBP Co-activator No Yes No CBP acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription, and binds as a multimeric complex with SRCs 8,48
SRA1 Co-activator No Yes No 25,45
NCOR2 Co-repressor No Yes Yes Nucleating platform to recruit histone deacetylase complexes. Binds in the presence of antagonist or the absence of hormone 16,27,33,54
JDP2 Co-activator Yes Yes No coactivates agonist or partial agonist mediated activity through an allosteric mechanism 55
Main Target Genes
Name Species Effect Technique Comments References
STAT5A Human Activated induced by PRB only in human breast cancer cells as detected by gene array 39
multidrug resistance 1B Mouse Activated Transient transfection observed in endometrial hyperplasia, induced by PRA only 30
HSD11B1 Human Activated HSD11B1 (11beta-hydroxysteroid dehydrogenase) is induced by both PRA and PRB in gene array analysis of human breast cancer cells 39
Ihh Mouse Activated Indian hedgehog (Ihh) is induced in overiectomized mice 3 hours after administration of progesterone 51
Main Target Genes Comments
Another gene activated by PR is FSH-beta (follicle stimulating hormone beta), this has been demostrated in sheep [56].
Tissue Distribution
Mammary gland, uterus, brain, muscle, testis, ovary
Species:  Human
Technique:  Northern, in situ, Western, immunohistology
References:  31,41
Tissue Distribution Comments
Both isoforms, PR-A and B, are generally expressed at equivalent levels. PR-A:B ratios can fluctuation in endometrial tissue throughout estrus/menstrual cycle progression, and ratios also can be perturbed in breast cancer and endometriosis. Similar expression patterns are seen in rodents.
Functional Assays
Progesterone treatment of estrogen treated ovariectomized mice results in decidualization of the endometrium
Species:  Mouse
Tissue:  Uterus
Response measured:  The inhibition of proliferation of the endometrial cells concurrent with differentation
References:  15,36
Mammary gland ductal tree branching and lobuloalveolar development
Species:  Mouse
Tissue:  Mammary gland
Response measured:  Mammary gland development
References:  3,19
Cell proliferation - treatment of PR positive breast cancer cells induces cell division
Species:  Human
Tissue:  Breast cancer cells and normal breast epithelial cells
Response measured:  Cell proliferation
References:  23,42
Physiological Consequences of Altering Gene Expression
Null mice: disruption of both PRA and B isoforms results in impaired sexual behavior, anovulation, uterine dysfunction, and reduced ductal branching and lobuloalveolar development in the mammary gland.
Species:  Mouse
Tissue: 
Technique:  Gene knockout
References:  29
Targeted overexpression of PRA in the mammary gland results in reduced induction of apoptosis
Species:  Mouse
Tissue: 
Technique:  Targeted overexpression
References:  47
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0004883 abnormal blood vessel healing PMID: 11518735 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0008271 abnormal bone ossification PMID: 18276762 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0000662 abnormal branching of the mammary ductal tree PMID: 7557380 
Pgrtm2Omc Pgrtm2Omc/Pgrtm2Omc
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0000662 abnormal branching of the mammary ductal tree PMID: 12897242 
Ncoa2tm1.1Ipc|Pgr+|Pgrtm2(cre)Lyd Ncoa2tm1.1Ipc/Ncoa2tm1.1Ipc,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ
MGI:1276533  MGI:97567  MP:0000662 abnormal branching of the mammary ductal tree PMID: 17045797 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0000130 abnormal cancellous bone morphology PMID: 18276762 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd
MGI:97567  MP:0003009 abnormal cytokine secretion PMID: 18026113 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0003845 abnormal decidualization PMID: 7557380 
Pgrtm1Omc Pgrtm1Omc/Pgrtm1Omc
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0003845 abnormal decidualization PMID: 10976068 
Ncoa2tm1.1Ipc|Pgr+|Pgrtm2(cre)Lyd Ncoa2tm1.1Ipc/Ncoa2tm1.1Ipc,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ
MGI:1276533  MGI:97567  MP:0003845 abnormal decidualization PMID: 17045797 
Ncoa1tm1Bwo|Ncoa2tm1.1Ipc|Pgr+|Pgrtm2(cre)Lyd Ncoa1tm1Bwo/Ncoa1tm1Bwo,Ncoa2tm1.1Ipc/Ncoa2tm1.1Ipc,Pgrtm2(cre)Lyd/Pgr+
involves: 129/Sv * 129S1/Sv * 129S2/SvPas * 129X1/SvJ
MGI:1276523  MGI:1276533  MGI:97567  MP:0003845 abnormal decidualization PMID: 17045797 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0009095 abnormal endometrial gland number PMID: 19439667 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001119 abnormal female reproductive system morphology PMID: 12403837 
Pgrtm3(rtTA2S*M2)Lyd Pgrtm3(rtTA2S*M2)Lyd/Pgrtm3(rtTA2S*M2)Lyd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:97567  MP:0001119 abnormal female reproductive system morphology PMID: 17941046 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0003967 abnormal follicle stimulating hormone level PMID: 10433223 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0005296 abnormal humerus morphology PMID: 18276762 
Pgrtm2Omc Pgrtm2Omc/Pgrtm2Omc
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001882 abnormal lactation PMID: 12897242 
Pgrtm2Omc Pgrtm2Omc/Pgrtm2Omc
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0009506 abnormal mammary gland alveolus morphology PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0009506 abnormal mammary gland alveolus morphology PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0000628 abnormal mammary gland development PMID: 7557380 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0000628 abnormal mammary gland development PMID: 12403837 
Pgrtm2Omc Pgrtm2Omc/Pgrtm2Omc
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0009504 abnormal mammary gland epithelium morphology PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0009504 abnormal mammary gland epithelium morphology PMID: 14667968 
Pgrtm2Omc Pgrtm2Omc/Pgrtm2Omc
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0006269 abnormal mammary gland growth during pregnancy PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0001881 abnormal mammary gland physiology PMID: 20029965 
Pgrtm4.2Lyd Pgrtm4.2Lyd/Pgrtm4.2Lyd
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6 * FVB/N
MGI:97567  MP:0001881 abnormal mammary gland physiology PMID: 20029965 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0001376 abnormal mating receptivity PMID: 7557380 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0004982 abnormal osteoclast morphology PMID: 18276762 
Pgrtm1Omc Pgrtm1Omc/Pgrtm1Omc
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0001928 abnormal ovulation PMID: 10976068 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001928 abnormal ovulation PMID: 12403837 
Pgrtm1.2Mlia Pgrtm1.2Mlia/Pgrtm1.2Mlia
involves: 129 * C57BL/6J
MGI:97567  MP:0001928 abnormal ovulation PMID: 16868919 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0003562 abnormal pancreatic beta cell physiology PMID: 12438645 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001919 abnormal reproductive system physiology PMID: 12403837 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 11518735 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0002566 abnormal sexual interaction PMID: 12403837 
Pgrtm3(rtTA2S*M2)Lyd Pgrtm3(rtTA2S*M2)Lyd/Pgrtm3(rtTA2S*M2)Lyd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:97567  MP:0002566 abnormal sexual interaction PMID: 17941046 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0000558 abnormal tibia morphology PMID: 18276762 
Pgrtm1Omc Pgrtm1Omc/Pgrtm1Omc
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0004014 abnormal uterine environment PMID: 10976068 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0001120 abnormal uterus morphology PMID: 7557380 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0001120 abnormal uterus morphology PMID: 19439667 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0009671 abnormal uterus physiology PMID: 20029965 
Pgrtm4.2Lyd Pgrtm4.2Lyd/Pgrtm4.2Lyd
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6 * FVB/N
MGI:97567  MP:0009671 abnormal uterus physiology PMID: 20029965 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0001134 absent corpus luteum PMID: 7557380 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001134 absent corpus luteum PMID: 12403837 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0008869 anovulation PMID: 7557380 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0008869 anovulation PMID: 20029965 
Pgrtm4.2Lyd Pgrtm4.2Lyd/Pgrtm4.2Lyd
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6 * FVB/N
MGI:97567  MP:0008869 anovulation PMID: 20029965 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0005560 decreased circulating glucose level PMID: 12438645 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0002773 decreased circulating luteinizing hormone level PMID: 10433223 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0002053 decreased incidence of induced tumors PMID: 14667968 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0010174 decreased mammary gland epithelium proliferation PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0001123 dilated uterus PMID: 7557380 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
MGI:109583  MGI:97567  MP:0004868 endometrial carcinoma PMID: 18632614 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu|Trp53tm1Brn Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu,Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
MGI:109583  MGI:97567  MGI:98834  MP:0004868 endometrial carcinoma PMID: 18632614 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0004868 endometrial carcinoma PMID: 19439667 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
MGI:109583  MGI:97567  MP:0009092 endometrium hyperplasia PMID: 18632614 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu|Trp53tm1Brn Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu,Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
MGI:109583  MGI:97567  MGI:98834  MP:0009092 endometrium hyperplasia PMID: 18632614 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0009092 endometrium hyperplasia PMID: 19439667 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0009251 enlarged endometrial glands PMID: 7557380 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu|Trp53tm1Brn Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu,Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
MGI:109583  MGI:97567  MGI:98834  MP:0004906 enlarged uterus PMID: 18632614 
Ncoa2tm1.1Ipc|Pgr+|Pgrtm2(cre)Lyd Ncoa2tm1.1Ipc/Ncoa2tm1.1Ipc,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ
MGI:1276533  MGI:97567  MP:0001728 failure of embryo implantation PMID: 17045797 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0001926 female infertility PMID: 7557380 
Pgrtm1Omc Pgrtm1Omc/Pgrtm1Omc
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0001926 female infertility PMID: 10976068 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0001926 female infertility PMID: 12403837 
Pgrtm1.2Mlia Pgrtm1.2Mlia/Pgrtm1.2Mlia
involves: 129 * C57BL/6J
MGI:97567  MP:0001926 female infertility PMID: 16868919 
Ncoa2tm1.1Ipc|Pgr+|Pgrtm2(cre)Lyd Ncoa2tm1.1Ipc/Ncoa2tm1.1Ipc,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ
MGI:1276533  MGI:97567  MP:0001926 female infertility PMID: 17045797 
Pgrtm3(rtTA2S*M2)Lyd Pgrtm3(rtTA2S*M2)Lyd/Pgrtm3(rtTA2S*M2)Lyd
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
MGI:97567  MP:0001926 female infertility PMID: 17941046 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0001926 female infertility PMID: 19439667 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0003356 impaired luteinization PMID: 7557380 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0005292 improved glucose tolerance PMID: 12438645 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0005605 increased bone mass PMID: 18276762 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0009347 increased cancellous bone thickness PMID: 18276762 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0002079 increased circulating insulin level PMID: 12438645 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0005124 increased circulating prolactin level PMID: 12897242 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0004148 increased cortical bone thickness PMID: 18276762 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0003058 increased insulin secretion PMID: 12438645 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0008870 increased mature ovarian follicle number PMID: 7557380 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0003645 increased pancreatic beta cell number PMID: 12438645 
Errfi1tm1Jwj|Pgr+|Pgrtm2(cre)Lyd Errfi1tm1Jwj/Errfi1tm1Jwj,Pgrtm2(cre)Lyd/Pgr+
involves: 129S1/Sv * 129X1/SvJ
MGI:1921405  MGI:97567  MP:0004904 increased uterus weight PMID: 19439667 
Pgr+|Pgrtm1Lyd Pgrtm1Lyd/Pgr+
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0002169 no abnormal phenotype detected PMID: 12403837 
Pgrtm1.1Mlia Pgrtm1.1Mlia/Pgrtm1.1Mlia
involves: 129 * C57BL/6J
MGI:97567  MP:0002169 no abnormal phenotype detected PMID: 16868919 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0005491 pancreatic islet hyperplasia PMID: 12438645 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6
MGI:109583  MGI:97567  MP:0002083 premature death PMID: 18632614 
Pgr+|Pgrtm2(cre)Lyd|Ptentm1Hwu|Trp53tm1Brn Pgrtm2(cre)Lyd/Pgr+,Ptentm1Hwu/Ptentm1Hwu,Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
MGI:109583  MGI:97567  MGI:98834  MP:0002083 premature death PMID: 18632614 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0002676 uterus hyperplasia PMID: 7557380 
Pgrtm1Omc Pgrtm1Omc/Pgrtm1Omc
involves: 129S7/SvEvBrd * C57BL/6J
MGI:97567  MP:0002676 uterus hyperplasia PMID: 10976068 
Pgrtm1Lyd Pgrtm1Lyd/Pgrtm1Lyd
involves: 129S7/SvEvBrd * C57BL/6
MGI:97567  MP:0002676 uterus hyperplasia PMID: 12403837 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
either: (involves: 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6)
MGI:97567  MP:0009080 uterus inflammation PMID: 7557380 
Pgrtm1Bwo Pgrtm1Bwo/Pgrtm1Bwo
involves: 129S7/SvEvBrd
MGI:97567  MP:0005489 vascular smooth muscle cell hyperplasia PMID: 11518735 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Breast cancer
OMIM:  114480
Comments: 
References:  4
Disease:  Endometrial cancer
OMIM:  608089
Comments: 
References:  10,52
Disease:  Endometriosis
OMIM:  607311
Role: 
Drugs: 
Comments: 
References:  2,9
Disease:  Pseudocorpus luteum insufficiency
OMIM:  264080
Role: 
Comments: 
References:  22
Biologically Significant Variants
Type:  Splice variant
Species:  Human
Description:  PR-B (progesterone receptor isoform B) is the full-length protein which strongly activates target genes  
Protein accession: 
References:  21
Type:  Splice variant
Species:  Human
Description:  PR-A (progesterone receptor isoform A):- N-terminally truncated isoform that is a weak transcriptional activator of specific target genes in a cell type dependent manner and also a strong repressor of transactivation by PRB and other steroid receptors
References:  17,21,53

References

Show »

1. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science277 (5328): 965-8. [PMID:9252329]

2. Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. (2000) Progesterone receptor isoform A but not B is expressed in endometriosis. J. Clin. Endocrinol. Metab.85 (8): 2897-902. [PMID:10946900]

3. Aupperlee MD, Smith KT, Kariagina A, Haslam SZ. (2005) Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. Endocrinology146 (8): 3577-88. [PMID:15878961]

4. Bamberger AM, Milde-Langosch K, Schulte HM, Löning T. (2000) Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm. Res.54 (1): 32-7. [PMID:11182633]

5. Bergink EW, van Meel F, Turpijn EW, van der Vies J. (1983) Binding of progestagens to receptor proteins in MCF-7 cells. J. Steroid Biochem.19 (5): 1563-70. [PMID:6645495]

6. Boonyaratanakornkit V, Melvin V, Prendergast P, Altmann M, Ronfani L, Bianchi ME, Taraseviciene L, Nordeen SK, Allegretto EA, Edwards DP. (1998) High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol. Cell. Biol.18 (8): 4471-87. [PMID:9671457]

7. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP. (2001) Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell8 (2): 269-80. [PMID:11545730]

8. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell90 (3): 569-80. [PMID:9267036]

9. Chwalisz K, DeManno D, Garg R, Larsen L, Mattia-Goldberg C, Stickler T. (2004) Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin. Reprod. Med.22 (2): 113-9. [PMID:15164306]

10. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ. (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc. Natl. Acad. Sci. U.S.A.99 (19): 12263-8. [PMID:12218173]

11. Edwards JP, West SJ, Marschke KB, Mais DE, Gottardis MM, Jones TK. (1998) 5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents. J. Med. Chem.41 (3): 303-10. [PMID:9464361]

12. Edwards JP, Zhi L, Pooley CL, Tegley CM, West SJ, Wang MW, Gottardis MM, Pathirana C, Schrader WT, Jones TK. (1998) Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists. J. Med. Chem.41 (15): 2779-85. [PMID:9667968]

13. Elbi C, Walker DA, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB. (2004) Molecular chaperones function as steroid receptor nuclear mobility factors. Proc. Natl. Acad. Sci. U.S.A.101 (9): 2876-81. [PMID:14978266]

14. Fensome A, Adams WR, Adams AL, Berrodin TJ, Cohen J, Huselton C, Illenberger A, Kern JC, Hudak VA, Marella MA et al.. (2008) Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348). J. Med. Chem.51 (6): 1861-73. [PMID:18318463]

15. Finn CA, Pope M. (1984) Vascular and cellular changes in the decidualized endometrium of the ovariectomized mouse following cessation of hormone treatment: a possible model for menstruation. J. Endocrinol.100 (3): 295-300. [PMID:6699534]

16. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. (2000) The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol. Cell. Biol.20 (9): 3102-15. [PMID:10757795]

17. Giangrande PH, Pollio G, McDonnell DP. (1997) Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J. Biol. Chem.272 (52): 32889-900. [PMID:9407067]

18. Hamann LG, Farmer LJ, Johnson MG, Bender SL, Mais DE, Wang MW, Crombie D, Goldman ME, Jones TK. (1996) Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether. J. Med. Chem.39 (9): 1778-89. [PMID:8627601]

19. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O'Malley BW, Lydon JP. (2003) Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids68 (10-13): 779-87. [PMID:14667968]

20. Johansson A, Helou K, Levan G. (1998) Cytogenetic localization of cancer-related genes in the rat and comparative mapping studies in human and mouse. Cytogenet. Cell Genet.81 (3-4): 217-21. [PMID:9730607]

21. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P. (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J.9 (5): 1603-14. [PMID:2328727]

22. Keller DW, Wiest WG, Askin FB, Johnson LW, Strickler RC. (1979) Pseudocorpus luteum insufficiency: a local defect of progesterone action on endometrial stroma. J. Clin. Endocrinol. Metab.48 (1): 127-32. [PMID:217888]

23. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. (2005) The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. Menopause12 (4): 468-74. [PMID:16037763]

24. Kubli-Garfias C, González-Flores O, Gómora-Arrati P, González-Mariscal G, Vázquez-Ramírez R, Beyer C. (2013) Bimodal binding and free energy of the progesterone receptor in the induction of female sexual receptivity by progesterone and synthetic progestins. J. Steroid Biochem. Mol. Biol.133: 43-50. [PMID:22960752]

25. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ, O'Malley BW. (1999) A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell97 (1): 17-27. [PMID:10199399]

26. Li X, Wong J, Tsai SY, Tsai MJ, O'Malley BW. (2003) Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol. Cell. Biol.23 (11): 3763-73. [PMID:12748280]

27. Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai MJ, O'Malley BW. (2002) Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. U.S.A.99 (12): 7940-4. [PMID:12048256]

28. Liu Z, Wong J, Tsai SY, Tsai MJ, O'Malley BW. (1999) Steroid receptor coactivator-1 (SRC-1) enhances ligand-dependent and receptor-dependent cell-free transcription of chromatin. Proc. Natl. Acad. Sci. U.S.A.96 (17): 9485-90. [PMID:10449719]

29. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Shyamala G, Conneely OM, O'Malley BW. (1995) Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev.9 (18): 2266-78. [PMID:7557380]

30. Mallick S, Horwitz SB. (1997) Transcriptional regulation of the murine multidrug resistance gene mdr1b by progesterone occurs via an indirect mechanism. DNA Cell Biol.16 (7): 807-18. [PMID:9260924]

31. Mangal RK, Wiehle RD, Poindexter AN, Weigel NL. (1997) Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid Biochem. Mol. Biol.63 (4-6): 195-202. [PMID:9459185]

32. Mattei MG, Krust A, Stropp U, Mattei JF, Chambon P. (1988) Assignment of the human progesterone receptor to the q22 band of chromosome 11. Hum. Genet.78 (1): 96-7. [PMID:3338797]

33. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM. (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell89 (3): 373-80. [PMID:9150137]

34. Naylor SL, Helen-Davis D, Hughes MR, O'Malley BW, Lalley PA. (1989) The progesterone receptor gene is on mouse chromosome 9. Cytogenet. Cell Genet.51: 1051.

35. Oñate SA, Prendergast P, Wagner JP, Nissen M, Reeves R, Pettijohn DE, Edwards DP. (1994) The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol. Cell. Biol.14 (5): 3376-91. [PMID:8164686]

36. Parandoosh Z, Crombie DL, Tetzke TA, Hayes JS, Heap RB, Wang MW. (1995) Progesterone and oestrogen receptors in the decidualized mouse uterus and effects of different types of anti-progesterone treatment. J. Reprod. Fertil.105 (2): 215-20. [PMID:8568763]

37. Petit-Topin I, Turque N, Fagart J, Fay M, Ulmann A, Gainer E, Rafestin-Oblin ME. (2009) Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol. Pharmacol.75 (6): 1317-24. [PMID:19289570]

38. Rewinkel J, Enthoven M, Golstein I, van der Rijst M, Scholten A, van Tilborg M, de Weys D, Wisse J, Hamersma H. (2008) 11-(pyridinylphenyl)steroids--a new class of mixed-profile progesterone agonists/antagonists. Bioorg. Med. Chem.16 (6): 2753-63. [PMID:18243712]

39. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. (2002) Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J. Biol. Chem.277 (7): 5209-18. [PMID:11717311]

40. Rižner TL, Brožič P, Doucette C, Turek-Etienne T, Müller-Vieira U, Sonneveld E, van der Burg B, Böcker C, Husen B. (2011) Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids76 (6): 607-15. [PMID:21376746]

41. Robker RL, Russell DL, Espey LL, Lydon JP, O'Malley BW, Richards JS. (2000) Progesterone-regulated genes in the ovulation process: ADAMTS-1 and cathepsin L proteases. Proc. Natl. Acad. Sci. U.S.A.97 (9): 4689-94. [PMID:10781075]

42. Saitoh M, Ohmichi M, Takahashi K, Kawagoe J, Ohta T, Doshida M, Takahashi T, Igarashi H, Mori-Abe A, Du B, Tsutsumi S, Kurachi H. (2005) Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology146 (11): 4917-25. [PMID:16123159]

43. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. (2003) Classification and pharmacology of progestins. Maturitas46 Suppl 1: S7-S16. [PMID:14670641]

44. Sheppard HM, Harries JC, Hussain S, Bevan C, Heery DM. (2001) Analysis of the steroid receptor coactivator 1 (SRC1)-CREB binding protein interaction interface and its importance for the function of SRC1. Mol. Cell. Biol.21 (1): 39-50. [PMID:11113179]

45. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M, Evans RM. (2001) Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev.15 (9): 1140-51. [PMID:11331609]

46. Shiozawa T, Shih HC, Miyamoto T, Feng YZ, Uchikawa J, Itoh K, Konishi I. (2003) Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium. J. Clin. Endocrinol. Metab.88 (2): 871-8. [PMID:12574227]

47. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH, Dale E. (1998) Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc. Natl. Acad. Sci. U.S.A.95 (2): 696-701. [PMID:9435255]

48. Smith CL, Oñate SA, Tsai MJ, O'Malley BW. (1996) CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc. Natl. Acad. Sci. U.S.A.93 (17): 8884-8. [PMID:8799122]

49. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, O'Malley BW. (1997) Steroid receptor coactivator-1 is a histone acetyltransferase. Nature389 (6647): 194-8. [PMID:9296499]

50. Sullivan WP, Toft DO. (1993) Mutational analysis of hsp90 binding to the progesterone receptor. J. Biol. Chem.268 (27): 20373-9. [PMID:8376394]

51. Takamoto N, Zhao B, Tsai SY, DeMayo FJ. (2002) Identification of Indian hedgehog as a progesterone-responsive gene in the murine uterus. Mol. Endocrinol.16 (10): 2338-48. [PMID:12351698]

52. Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. (2005) Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am. J. Epidemiol.161 (5): 442-51. [PMID:15718480]

53. Vegeto E, Shahbaz MM, Wen DX, Goldman ME, O'Malley BW, McDonnell DP. (1993) Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol.7 (10): 1244-55. [PMID:8264658]

54. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP. (1998) The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell. Biol.18 (3): 1369-78. [PMID:9488452]

55. Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP. (2002) Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol. Cell. Biol.22 (15): 5451-66. [PMID:12101239]

56. Webster JC, Pedersen NR, Edwards DP, Beck CA, Miller WL. (1995) The 5'-flanking region of the ovine follicle-stimulating hormone-beta gene contains six progesterone response elements: three proximal elements are sufficient to increase transcription in the presence of progesterone. Endocrinology136 (3): 1049-58. [PMID:7867558]

57. Zhi L, Tegley CM, Kallel EA, Marschke KB, Mais DE, Gottardis MM, Jones TK. (1998) 5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists. J. Med. Chem.41 (3): 291-302. [PMID:9464360]

58. Zhi L, Tegley CM, Pio B, Edwards JP, Jones TK, Marschke KB, Mais DE, Risek B, Schrader WT. (2003) Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators. Bioorg. Med. Chem. Lett.13 (12): 2071-4. [PMID:12781197]

How to cite this page

3C. 3-Ketosteroid receptors: Progesterone receptor. Last modified on 24/10/2014. Accessed on 28/11/2014. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627.